192 related articles for article (PubMed ID: 33270606)
1. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.
Harro CM; Perez-Sanz J; Costich TL; Payne KK; Anadon CM; Chaurio RA; Biswas S; Mandal G; Rigolizzo KE; Sprenger KB; Mine JA; Showe LC; Yu X; Liu K; Rodriguez PC; Pinilla-Ibarz J; Sokol L; Conejo-Garcia JR
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33270606
[TBL] [Abstract][Full Text] [Related]
2. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
3. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
[TBL] [Abstract][Full Text] [Related]
5. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas.
Grzanka A; Grzanka D; Gagat M; Tadrowski T; Sokołowska-Wojdyło M; Marszałek A; Placek W
Pol J Pathol; 2012 Jun; 63(2):101-5. PubMed ID: 22864778
[TBL] [Abstract][Full Text] [Related]
6. SATB1 Defines a Subtype of Cutaneous CD30
Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
[TBL] [Abstract][Full Text] [Related]
7. SATB1 in Malignant T Cells.
Fredholm S; Willerslev-Olsen A; Met Ö; Kubat L; Gluud M; Mathiasen SL; Friese C; Blümel E; Petersen DL; Hu T; Nastasi C; Lindahl LM; Buus TB; Krejsgaard T; Wasik MA; Kopp KL; Koralov SB; Persson JL; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Becker JC; Ødum N
J Invest Dermatol; 2018 Aug; 138(8):1805-1815. PubMed ID: 29751003
[TBL] [Abstract][Full Text] [Related]
8. SATB1-mediated chromatin landscape in T cells.
Zelenka T; Spilianakis C
Nucleus; 2020 Dec; 11(1):117-131. PubMed ID: 33356851
[TBL] [Abstract][Full Text] [Related]
9. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Bieniek A; Dziegiel P
Anticancer Res; 2016 Jan; 36(1):189-97. PubMed ID: 26722043
[TBL] [Abstract][Full Text] [Related]
10. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.
Miyashiro D; Souza BCE; Torrealba MP; Manfrere KCG; Sato MN; Sanches JA
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055124
[TBL] [Abstract][Full Text] [Related]
11. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
Wu R; Zippin JH; Magro C
Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
13. Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma.
Grzanka D; Gagat M; Izdebska M; Marszałek A
Oncol Rep; 2015 Jan; 33(1):250-66. PubMed ID: 25384658
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
16. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
Choi MY; Lechowicz MJ
Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
19. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.
Campbell JJ; Clark RA; Watanabe R; Kupper TS
Blood; 2010 Aug; 116(5):767-71. PubMed ID: 20484084
[TBL] [Abstract][Full Text] [Related]
20. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
